[go: up one dir, main page]

WO2008061902A3 - Targeting of l-3-hydroxyacyl-coenzyme a dehydrogenase, short chain (hadhsc) in disorders of glucose homeostasis - Google Patents

Targeting of l-3-hydroxyacyl-coenzyme a dehydrogenase, short chain (hadhsc) in disorders of glucose homeostasis Download PDF

Info

Publication number
WO2008061902A3
WO2008061902A3 PCT/EP2007/062114 EP2007062114W WO2008061902A3 WO 2008061902 A3 WO2008061902 A3 WO 2008061902A3 EP 2007062114 W EP2007062114 W EP 2007062114W WO 2008061902 A3 WO2008061902 A3 WO 2008061902A3
Authority
WO
WIPO (PCT)
Prior art keywords
hadhsc
hydroxyacyl
coenzyme
dehydrogenase
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/062114
Other languages
French (fr)
Other versions
WO2008061902A2 (en
Inventor
Geert Martens
Danny Pipeleers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opus NV
Vrije Universiteit Brussel VUB
Universite Libre de Bruxelles ULB
Original Assignee
Opus NV
Vrije Universiteit Brussel VUB
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opus NV, Vrije Universiteit Brussel VUB, Universite Libre de Bruxelles ULB filed Critical Opus NV
Publication of WO2008061902A2 publication Critical patent/WO2008061902A2/en
Publication of WO2008061902A3 publication Critical patent/WO2008061902A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides methods, uses, agents, pharmaceutical formulations and kits for the treatment of disorders of glucose homeostasis and/or for modulating the endogenous production of insulin in subjects. The invention also relates to methods, uses, agents, compositions and kits for modulating the endogenous insulin production by isolated cells or tissues. More in particular, the invention teaches to target L-3-hydroxyacyl-coenzyme A dehydrogenase, short chain (HADHSC). In addition, the invention also provides screening assays to identify agents that modulate the expression and/or the activity of HADHSC and can be useful in the above aspects of the invention.
PCT/EP2007/062114 2006-11-24 2007-11-09 Targeting of l-3-hydroxyacyl-coenzyme a dehydrogenase, short chain (hadhsc) in disorders of glucose homeostasis Ceased WO2008061902A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06447125.3 2006-11-24
EP06447125 2006-11-24

Publications (2)

Publication Number Publication Date
WO2008061902A2 WO2008061902A2 (en) 2008-05-29
WO2008061902A3 true WO2008061902A3 (en) 2009-03-05

Family

ID=37989044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/062114 Ceased WO2008061902A2 (en) 2006-11-24 2007-11-09 Targeting of l-3-hydroxyacyl-coenzyme a dehydrogenase, short chain (hadhsc) in disorders of glucose homeostasis

Country Status (1)

Country Link
WO (1) WO2008061902A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058142A2 (en) * 2003-12-16 2005-06-30 Emory University Diabetes diagnostic
WO2006017171A2 (en) * 2004-07-13 2006-02-16 Metabolex, Inc. Methods of diagnosing & treating obesity, diabetes and insulin resistance

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058142A2 (en) * 2003-12-16 2005-06-30 Emory University Diabetes diagnostic
WO2006017171A2 (en) * 2004-07-13 2006-02-16 Metabolex, Inc. Methods of diagnosing & treating obesity, diabetes and insulin resistance

Also Published As

Publication number Publication date
WO2008061902A2 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2006084209A3 (en) Rnai expression constructs
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
WO2006004910A3 (en) Improved bispecific antibodies
WO2007067504A3 (en) Lactam compounds and methods of using the same
WO2006116353A8 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
WO2008036419A3 (en) Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker
WO2009099628A3 (en) Compositions and methods for influencing recovery from strenuous physical activity
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2006050058A3 (en) Methods of detection and therapy of inflamed tissues using immune modulation
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
WO2008002449A3 (en) Glycomimetic inhibitors of siglec-8
WO2008151005A3 (en) Compositions and methods for tissue repair
WO2007037653A8 (en) Use of mesenchymal stem cells genetically modified to express a suicide gene for treating a cancer
MY144970A (en) Heterocyclic compounds
WO2006078503A3 (en) Compositions for modulation of parp and methods for screening for same
WO2007047680A3 (en) Increasing the activity of radical s-adenosyl methionine (sam) enzymes
WO2009102366A3 (en) Expression of orphan gpr64 in inflammatory diseases
WO2010057647A3 (en) Methods and compositions for the diagnosis and treatment of diabetes
WO2007005502A3 (en) Methods and compositions for treating diseases targeting cdcp1
WO2006091841A3 (en) Compositions and their uses directed to il-4r alpha

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07857205

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07857205

Country of ref document: EP

Kind code of ref document: A2